Literature DB >> 18314255

Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.

Umberto Capitanio1, Vincenzo Scattoni, Massimo Freschi, Alberto Briganti, Andrea Salonia, Andrea Gallina, Renzo Colombo, Pierre I Karakiewicz, Patrizio Rigatti, Francesco Montorsi.   

Abstract

BACKGROUND: Controversies exist about the most appropriate management for patients with incidental prostate cancer after surgery for benign prostatic hyperplasia (BPH).
OBJECTIVES: To test the accuracy of preoperative clinical variables in predicting the presence of residual disease and biochemical recurrence in patients with incidental prostate cancer treated with radical retropubic prostatectomy. DESIGN, SETTING, AND PARTICIPANTS: We analyzed 126 T1a-T1b prostate cancers diagnosed at surgery for BPH between 1995 and 2007. INTERVENTION: All patients underwent radical retropubic prostatectomy within 6 mo of surgery for BPH. MEASUREMENTS: Univariate and multivariate logistic regression models addressed the association between the predictors (age, prostate-specific antigen [PSA] before and after surgery for BPH, T1a-T1b stage, prostate volume, and Gleason score at surgery for BPH) and the presence of residual cancer at radical retropubic prostatectomy. Cox proportional hazards regression analyses tested the relationship between the same predictors and the rate of biochemical recurrence after radical retropubic prostatectomy. RESULTS AND LIMITATIONS: Seventy-five (59.5%) patients were stage T1a and 51 (40.5%) were stage T1b. At radical retropubic prostatectomy, 21 (16.7%) patients were pT0 and seven (5.6%) patients had extraprostatic disease (pT3). PSA before and after surgery for BPH and Gleason score at surgery for BPH were the only independent predictors of residual cancer at radical retropubic prostatectomy (all p<0.04). Stage (T1a vs T1b) did not predict residual cancer or the rate of biochemical recurrence. With a mean follow-up of 57 mo, the 5- and 10-yr biochemical recurrence-free survival rates were 92% and 87%, respectively. PSA after surgery for BPH and Gleason score at surgery for BPH were the only significant multivariate predictors of biochemical recurrence (all p<0.04). The main limitation of this study is the requirement of an external validation before implementation of the clinical recommendations.
CONCLUSION: PSA measured before and after surgery for BPH and Gleason score at surgery for BPH were the only significant predictors of the presence of residual cancer at radical retropubic prostatectomy. PSA measured after surgery for BPH and Gleason score at surgery for BPH were the only independent predictors of biochemical recurrence after radical retropubic prostatectomy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18314255     DOI: 10.1016/j.eururo.2008.02.018

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  14 in total

1.  Significance of prostate-specific antigen-related factors in incidental prostate cancer treated by holmium laser enucleation of the prostate.

Authors:  Satoshi Otsubo; Akira Yokomizo; Osamu Mochida; Masaki Shiota; Katsunori Tatsugami; Junich Inokuchi; Seiji Naito
Journal:  World J Urol       Date:  2014-05-08       Impact factor: 4.226

2.  Survival after incidental prostate cancer diagnosis at transurethral resection of prostate: 10-year outcomes.

Authors:  S Ahmad; F O'Kelly; R P Manecksha; I M Cullen; R J Flynn; T E D McDermott; R Grainger; J A Thornhill
Journal:  Ir J Med Sci       Date:  2011-09-11       Impact factor: 1.568

3.  [A paradigm shift. Defensive strategies for the treatment of localized prostate cancer in the new S3 guideline].

Authors:  L Weissbach; C Schaefer; A Heidenreich
Journal:  Urologe A       Date:  2010-02       Impact factor: 0.639

4.  An improved prognostic model for stage T1a and T1b prostate cancer by assessments of cancer extent.

Authors:  Ramzi Rajab; Gabrielle Fisher; Michael W Kattan; Christopher S Foster; Henrik Møller; Tim Oliver; Victor Reuter; Peter T Scardino; Jack Cuzick; Daniel M Berney
Journal:  Mod Pathol       Date:  2010-09-10       Impact factor: 7.842

5.  [TNM-Classification of localized prostate cancer : The clinical T-category does not correspond to the required demands].

Authors:  J Herden; A Heidenreich; L Weißbach
Journal:  Urologe A       Date:  2016-12       Impact factor: 0.639

6.  An Advanced but Traditional Technique of Transurethral Resection of the Prostate in Order not to Overlook Stage T1 Prostate Cancer.

Authors:  Masaru Morita; Takeshi Matsuura
Journal:  Curr Urol       Date:  2012-04-30

7.  Preoperative clinical factors for diagnosis of incidental prostate cancer in the era of tissue-ablative surgery for benign prostatic hyperplasia: a korean multi-center review.

Authors:  Changhee Yoo; Cheol Young Oh; Se Joong Kim; Sun Il Kim; Young Sig Kim; Jong Yeon Park; Do Hwan Seong; Yun Seob Song; Won Jae Yang; Hyun Chul Chung; In Rae Cho; Sung Yong Cho; Sang Hyeon Cheon; Sungjoon Hong; Jin Seon Cho
Journal:  Korean J Urol       Date:  2012-06-19

8.  Clinical experiences of incidental prostate cancer after transurethral resection of prostate (TURP) according to initial treatment: a study of a Korean high volume center.

Authors:  Dong Hoon Lee; Doo Yong Chung; Kwang-suk Lee; In Kyong Kim; Koon Ho Rha; Young Deuk Choi; Byung Ha Chung; Sung Joon Hong; Jang Hwan Kim
Journal:  Yonsei Med J       Date:  2014-01       Impact factor: 2.759

Review 9.  Are all procedures for benign prostatic hyperplasia created equal? A systematic review on post-procedural PSA dynamics and its correlation with relief of bladder outlet obstruction.

Authors:  Abhishek Bhat; Ruben Blachman-Braun; Thomas R W Herrmann; Hemendra N Shah
Journal:  World J Urol       Date:  2021-07-02       Impact factor: 3.661

10.  Incidental prostate cancer in transurethral resection of the prostate specimens in the modern era.

Authors:  Brandon Otto; Christopher Barbieri; Richard Lee; Alexis E Te; Steven A Kaplan; Brian Robinson; Bilal Chughtai
Journal:  Adv Urol       Date:  2014-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.